Initial fixed low-versus moderate-dose hydroxyurea assignment in the long-term follow-up of the SPRINT cohort
In this pragmatic long-term follow-up of the SPRINT randomized trial cohort, rates of recurrent stroke and all-cause mortality did not differ significantly by an initial fixed low- versus moderate-dose of hydroxyurea over 4.9 years, with events clustering in the first year.
Authors
- Ibrahim Musa Idris (ORCID: https://orcid.org/0000-0002-8363-3094)
- Michael Rutledge DeBaun (ORCID: https://orcid.org/0000-0002-0574-1604)
- Mark Rodeghier (ORCID: https://orcid.org/0000-0001-7258-0073)
- Shehu Umar Abdullahi (ORCID: https://orcid.org/0000-0001-5567-9629)
- Hauwa Inuwa
- Surayya Murtala Sunusi (ORCID: https://orcid.org/0000-0002-9985-1635)
- Abdulkadir Halifa Yusuf
- Khadijah A Bulama
- Shamsu Muhammad Iguda (ORCID: https://orcid.org/0000-0001-8977-8684)
Institutions
- Vanderbilt University (US)
- Aminu Kano Teaching Hospital (NG)
- Bayero University Kano (NG)
Publication Details
- Journal
- Blood
- Published
- 2026-10-26
- DOI
- https://doi.org/10.1182/blood.2026034384
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00